Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10237328 | 0.85 | KDM4E (0.35) | MAPTTP53RXFP1KDM4EALDH1A1 | |
| SCHEMBL1728318 | 0.78 | MAPT (0.55) | MAPTTP53RXFP1KDM4EALDH1A1 | |
| SCHEMBL4731382 | 0.76 | KDM4E (0.41) | MAPTTP53RXFP1KDM4EALDH1A1 | |
| SCHEMBL4155399 | 0.76 | KDM4E (0.38) | MAPTTP53RXFP1KDM4EALDH1A1 | |
| SCHEMBL4155397 | 0.76 | KDM4E (0.38) | MAPTTP53RXFP1KDM4EALDH1A1 | |
| SCHEMBL4143220 | 0.75 | MAPT (0.45) | MAPTPOLBTP53KDM4EALDH1A1 | |
| SCHEMBL4795067 | 0.74 | ALDH1A1 (0.38) | MAPTTP53RXFP1KDM4EALDH1A1 | |
| SCHEMBL4795076 | 0.74 | ALDH1A1 (0.38) | MAPTTP53RXFP1KDM4EALDH1A1 | |
| SCHEMBL4794530 | 0.74 | KDM4E (0.35) | MAPTTP53RXFP1KDM4EALDH1A1 | |
| SCHEMBL4794527 | 0.74 | KDM4E (0.35) | MAPTTP53RXFP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403860-B1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE AS HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-8193372-B2 | Phosphothiophene and phosphothiazole HCV polymerase inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100233123-A1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233123-A1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | PPP3CB, POLR2E, PSAT1 | PLA2G2A 2000/4885MAPT 1176/4885POLB 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.